What hyperbaric oxygen therapy does and does not do

The phrase "FDA approved" does not apply to hyperbaric chambers, and once you know why, a great deal of the marketing in this market becomes easier to read. Hyperbaric chambers are Class II devices cleared through the premarket notification pathway under section 510(k) of the Food, Drug and Cosmetic Act. FDA's product classification record for "chamber, hyperbaric" lists regulation number 868.5470, device class 2, submission type 510(k), product code CBF, and names two recognised consensus standards — NFPA 99 and ASME PVHO-1 (FDA Product Classification, product code CBF).

A 510(k) clearance is a finding of substantial equivalence to an already legally marketed device. It is not a standalone finding of safety and effectiveness, which is what premarket approval under section 515 delivers and which is reserved for Class III devices. FDA restated the position for this product category in plain words in 2025: "HBOT devices are Class II medical devices and are cleared by the FDA through the 510(k) process. FDA-cleared HBOT devices can be identified by searching for Product Code CBF in the 510(k) database" (FDA Letter to Health Care Providers, 25 August 2025).

So when a brochure says a chamber is "FDA approved for 13 conditions," two things are wrong at once: the verb, and the implication that clearance is a regulatory endorsement of clinical benefit. FDA's own heading over that list of conditions was "Conditions for which hyperbaric chambers are cleared for marketing by the FDA."

The cleared indications, quoted with their date and status

FDA maintained a consumer page carrying that list. It matters how you cite it, because the live URL now returns FDA's Page Not Found screen, and we could not find a replacement page on fda.gov carrying the same list. The text below is quoted from the Internet Archive capture, whose own footer reads "Content current as of: 07/26/2021." Anyone presenting this as FDA's current published position without saying that is misrepresenting it.

Conditions for which hyperbaric chambers are cleared for marketing by the FDA … As of July 2021, the FDA has cleared hyperbaric chambers for the following disorders: Air and gas bubbles in blood vessels · Anemia (severe anemia when blood transfusions cannot be used) · Burns (severe and large burns treated at a specialized burn center) · Carbon monoxide poisoning · Crush injury · Decompression sickness (diving risk) · Gas gangrene · Hearing loss (complete hearing loss that occurs suddenly and without any known cause) · Infection of the skin and bone (severe) · Radiation injury · Skin graft flap at risk of tissue death · Vision loss (when sudden and painless in one eye due to blockage of blood flow) · Wounds (non-healing, diabetic foot ulcers)

FDA consumer update, archived capture; content current as of 26 July 2021. The original URL now returns Page Not Found.

A second, clinically worded FDA list exists, distributed by FDA's Center for Devices and Radiological Health to state medical boards in August 2013. It differs materially: it names intracranial abscess, necrotising soft tissue infections and refractory osteomyelitis as separate items, where the 2021 consumer list compresses them into "infection of the skin and bone (severe)", and the 2021 list adds sudden hearing loss (FDA CDRH letter of 22 August 2013, reproduced in Virginia Board of Medicine Board Briefs #73). If you see a page blending the two lists, or presenting a count of fourteen, it has not read either source. Quote one, and date it.

What FDA has said is not established

This is the half of the record that sellers omit. FDA has repeatedly and specifically named uses that are neither cleared nor established. In a 2021 consumer bulletin FDA wrote that it "is aware there are some hyperbaric oxygen treatment centers promoting hyperbaric oxygen chambers for uses that have not been cleared or approved by the FDA, such as treatment of cancer, Lyme disease, autism, or Alzheimer's disease" (FDA bulletin, 26 July 2021).

Its 2013 consumer publication, titled "Hyperbaric Oxygen Therapy: Don't Be Misled," opens: "No, hyperbaric oxygen therapy (HBOT) has not been clinically proven to cure or be effective in the treatment of cancer, autism, or diabetes." The same document lists conditions for which FDA stated safety and effectiveness had not been established: AIDS/HIV, Alzheimer's disease, asthma, Bell's palsy, brain injury, cerebral palsy, depression, heart disease, hepatitis, migraine, multiple sclerosis, Parkinson's disease, spinal cord injury, sports injury, and stroke (FDA Consumer Health Information, August 2013).

We are a chamber company writing that down on our own website, so it is worth being explicit about what it means for a purchase. If your interest in a chamber rests on one of those conditions, the regulatory record does not support the purchase, and no page on this site will pretend otherwise. That is a decision to make with a clinician, not with a salesperson.

Prescription status, which is not where most people look for it

21 CFR 868.5470 — the classification regulation itself — is two sentences long and contains no prescription-device language at all. The exact text reads: "A hyperbaric chamber is a device that is intended to increase the environmental oxygen pressure to promote the movement of oxygen from the environment to a patient's tissue by means of pressurization that is greater than atmospheric pressure. This device does not include topical oxygen chambers for extremities … Classification. Class II (performance standards)" (official CFR text via GPO; current status at eCFR § 868.5470).

Prescription status arrives from two other places. First, the general prescription-device rule at 21 CFR 801.109, which conditions the labelling exemption on the device being "sold only to or on the prescription or other order of such practitioner for use in the course of his professional practice," with the label bearing "Rx only" or the equivalent caution statement (21 CFR 801.109, GPO text). Second, the individual clearances. The Indications for Use enclosure for the Summit to Sea fabric chambers states "Caution: Federal Law restricts this device to sale by or on the order of a physician," with prescription use checked and over-the-counter use not checked (K072757 clearance package), and the Revitalair 430+ clearance is marked "Prescription – Rx Only: Yes" (K220290).

FDA has also said it in one sentence: "Hyperbaric oxygen chambers are prescription devices, and we have received numerous complaints … regarding their use in facilities not operated by a licensed physician" (FDA CDRH letter, 22 August 2013). A database check is consistent: of 144 listings under product code CBF in FDA's Global UDI Database, 138 are flagged prescription and six are flagged neither prescription nor over-the-counter. None are flagged over-the-counter (openFDA UDI count by prescription flag).

How to verify a clearance claim yourself

You do not have to take a manufacturer's regulatory paragraph on trust, and you should not. Every clearance has a K-number and a named applicant, and both are searchable. There are 69 clearances on record under product code CBF, the earliest K790693 from 1979 and the most recent K240569, decided 21 November 2024 (openFDA 510(k) records for CBF).

Ask any seller, including us, for the K-number behind the claim, then confirm that the applicant name on the record is the company you think it is. This is not a hypothetical exercise: FDA's 2013 warning letter to OxyHealth alleged the firm was "marketing hyperbaric chambers in the United States without marketing clearance or approval" (FDA Warning Letter, 8 August 2013, PDF hosted by the recipient; FDA's own copy was not retrievable), and the clearance number cited on that company's public regulatory page, K041007, is held in FDA's database under a different applicant name for differently named models. Confirm the record, not the brochure.